BETA
Your AI-Trained Oncology Knowledge Connection!
IMMU-132 Encouraging in Previously Treated Metastatic Lung Cancer
The investigational agent IMMU-32 is well-tolerated in patients with previously-treated metastatic lung cancer, and interim survival data are “encouraging.”
Bevacizumab Improved Survival in Mesothelioma
Adding the angiogenesis inhibitor bevacizumab to standard cisplatin/pemetrexed chemotherapy prolonged survival by more than 2 months among patients with malignant pleural mesothelioma.
Adjuvant Chemo-Immunotherapy May Improve NSCLC Survival
Postsurgical chemo-immunotherapy offers improved survival rates for patients with NSCLC, compared to adjuvant chemotherapy alone, according to a small phase III study.
First-line Nivolumab/Ipilimumab Demonstrate ‘Deep,’ ‘Durable’ Activity
Treatment with nivolumab and ipilimumab is clinically active and has a manageable safety profile for chemotherapy-naive patients diagnosed with advanced NSCLC.
Early Recognition of Immunotherapy Toxicities Essential
Oncology teams need to spot emerging immune-related adverse events associated with immunotherapies early in order to avoid treatment discontinuation.
